Guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism

被引:77
|
作者
Ruiz-Stewart, I
Tiyyagura, SR
Lin, JE
Kazerounian, S
Pitari, GM
Schulz, S
Martin, E
Murad, F
Waldman, SA [1 ]
机构
[1] Thomas Jefferson Univ, Dept Med, Div Clin Pharmacol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA
[3] Univ Texas, Hlth Sci Ctr, Inst Mol Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA
关键词
D O I
10.1073/pnas.0305080101
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Defending cellular integrity against disturbances in intracellular concentrations of ATP ([ATP](i)) is predicated on coordinating the selection of substrates and their flux through metabolic pathways (metabolic signaling), ATP transfer from sites of production to utilization (energetic signaling), and the regulation of processes consuming energy (cell signaling). Whereas NO and its receptor, soluble guanylyl cyclase (sGC), are emerging as key mediators coordinating ATP supply and demand, mechanisms coupling this pathway with metabolic and energetic signaling remain undefined. Here, we demonstrate that sGC is a nucleotide sensor whose responsiveness to NO is regulated by [ATP](i). Indeed, ATP inhibits purified sGC with a K-i predicting >60% inhibition of NO signaling in cells maintaining physiological [nucleotide](i). ATP inhibits sGC by interacting with a regulatory site that prefers ATIP > GTP. Moreover, alterations in [ATP](i), by permeabilization and nucleotide clamping or inhibition of mitochondrial ATIP synthase, regulate NO signaling by sGC. Thus, [ATP](i) serves as a "gain control" for NO signaling by sGC. At homeostatic [ATP](i), NO activation of sGC is repressed, whereas insults that reduce [ATP](i), derepress sGC and amplify responses to NO. Hence, sGC forms a key synapse integrating metabolic, energetic, and cell signaling, wherein ATP is the transmitter, allosteric inhibition the coupling mechanism, and regulated accumulation of cGMP the response.
引用
收藏
页码:37 / 42
页数:6
相关论文
共 50 条
  • [1] Soluble guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism.
    Tiyyagura, SR
    Ruiz-Stewart, I
    Kazerounian, S
    Lin, E
    Pitari, GM
    Schulz, S
    Martin, E
    Murad, F
    Waldman, SA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P46 - P46
  • [2] Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor
    Montfort, William R.
    Wales, Jessica A.
    Weichsel, Andrzej
    ANTIOXIDANTS & REDOX SIGNALING, 2017, 26 (03) : 107 - 121
  • [3] Guanylyl cyclase independent signaling of nitric oxide via TRPA1
    Berr, C.
    Schaefer, E. A. M.
    Gudermann, T.
    Buech, T. R. H.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S9 - S9
  • [4] On the activation of soluble guanylyl cyclase by nitric oxide
    Bellamy, TC
    Wood, J
    Garthwaite, J
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (01) : 507 - 510
  • [5] Nitric oxide as a regulator of soluble guanylyl cyclase
    Burstyn, JN
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 573 - INOR
  • [6] Soluble guanylyl cyclase: The nitric oxide receptor
    Martin, E
    Berka, V
    Tsai, AL
    Murad, F
    NITRIC OXIDE, PT E, 2005, 396 : 478 - 492
  • [7] Regulation of nitric oxide and soluble guanylyl cyclase
    Krumenacker, J
    Hanafy, KA
    Murad, F
    BRAIN RESEARCH BULLETIN, 2004, 62 (06) : 505 - 515
  • [8] Nitric oxide/soluble guanylyl cyclase signaling in melanocytes: new aspects for modulation of pigmentation
    Ivanova, Krassimira
    Das, Pranab K.
    Gerzer, Rupert
    PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 316 - 316
  • [9] Per-ARNT-Sim Domains in Nitric Oxide Signaling by Soluble Guanylyl Cyclase
    Montfort, William R.
    JOURNAL OF MOLECULAR BIOLOGY, 2024, 436 (03)
  • [10] NO-sensitive guanylyl cyclase: Dissociation of nitric oxide
    Russwurm, M
    Koesling, D
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R40 - R41